Enterprise Value
2.188B
Cash
443M
Avg Qtr Burn
-45.91M
Short % of Float
8.66%
Insider Ownership
0.09%
Institutional Own.
74.16%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RYTELO™ (Imetelstat) (GRN163L) Details Myelodysplastic syndrome | Approved Quarterly sales | |
Imetelstat (GRN163L) Details Myelofibrosis | Phase 3 Interim Update | |
Imetelstat (GRN163L) Details Myelodysplastic syndrome, Acute myeloid leukemia | Phase 2 Data readout | |
Imetelstat (GRN163L)+ ruxolitinib Details Myelofibrosis | Phase 1 Data readout |